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Randomization in Cancer Clinical Trials:
Permutation Test and Development of a
Computer Program
by Yasuo Ohashi*
When analyzing cancer clinical trial data where the treatment allocation is done using dynamic bal-
ancing methods such as the minimization method for balancing the distribution ofimportant prognostic
factors in each arm, conservativeness occurs if such a randomization scheme is ignored and a simple
unstratified analysis is carried out. In this paper, the above conservativeness isdemonstrated by computer
simulation, and the development of a computer program that carries out permutation tests of the log-
rankstatisticsforclinicaltrialdatawheretheallocationis donebytheminimizationmethodorastratified
permuted block design is introduced. We are planning to use this program in practice to supplement a
usual stratified analysis and model-based methods such as the Cox regression.
The most serious problem in cancer clinical trials in Japan is how to carry out the quality control or
data management in trials that are initiated and conducted by researchers without support from phar-
maceuticalcompanies. Inthefinalsectionofthispaper,oneinternationalcollaborativeworkfordeveloping
international guidelines on data management in clinical trials ofbladdercancer is briefly introduced, and
the differences between the system adopted in US/European statistical centers and the Japanese system
is described.
Background
As seen in the guidelines by Simon and Wittes (1),
highqualityisbeingrequiredin cancerclinicaltrialdata
for raising the reliability and comparability of trials,
and this pressure from abroad is now influencing the
designandmanagementofcancerclinicaltrialsinJapan.
Until a few years ago, the randomization has been done
almost exclusively bythe envelop method inJapan, and
a high rate of ineligibility and protocol violations have
often deteriorated the reliability of the results. Re-
cently, the central registration and randomization sys-
tem by using a telephone call (or a facsimile) with a
check ofthe eligibility criteria ofeach patient is rapidly
spreading, and some medical researchers have a some-
what radical opinion that a trial by the envelop method
is not scientifically evaluative.
Ifthis centralized registration system is adopted and
works well, it becomes possible to incorporate dynamic
balancing methods for reducing a possible imbalance in
the patients' distribution of important prognostic fac-
tors [see Kalish and Begg (2) for a review ofproposed
methods]. In many U.S./European cooperative phase
III cancer clinical trials coordinated by well-organized
statistical centers, the dynamic balancing is a usual
practice ratherthan an exception, and the mininiization
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method (3) with some modifications is usually adopted
(4). InJapan, Sakamoto etal. (5)reported thattheyare
conducting a trial of gastrointestinal cancer with the
minimiization method.
Conservatism in Analysis
It is well known (6) that conservativeness occurs in
analyzing clinical trial data if stratifying variables are
ignored when the patient allocation is done by a strat-
ified(block)design. Anderson(personalcommunication)
and Forsythe and Stitt (7)pointed outthatitalsooccurs
forthe minimization method. Kalish and Begg (8) stud-
ied the impact of the treatment allocation on nominal
significance levels and concluded that "(nominal p-val-
ues)arenotlikelytobeseverelydistortediftheanalysis
is stratified by important covariates used as allocation
prompts." In many U.S./European centers that are us-
ing the minimization method, the stratified analysis is
routine, and the conclusion by Kalish and Begg seems
to support their strategy. The number of stratifying
variables, however, is usually two or three and some-
times overfourin U.S./Europeantypical cancerclinical
trials, and it also seems that the number of strata is
sometimes over ten. It is easily expected that the ef-
ficiency (power) loss may not be negligible if unneces-
sarycovariates areusedindynamicbalancing;however,
the reseaich in this respect is not yet adequate. More-
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clinical trials, institutes are treated as different levels
of covariate and incorporated in the minimization pro-
cess. The above conservativeness will occur ifthey are
ignored in analysis, and the efficiency loss will occur if
the stratification is done as to institutions.
Table 1 is the result ofour computer simulation that
shows the conservativeness ofthe log-rank test statis-
tics due to ignoring the covariates used in the minimi-
zation allocation. In this simulation we assume three
binary (O or 1) covariates, x1, x2, and x8, and they in-
fluence the survival time (end point) through a propor-
tional hazard model:
X(t;x) = XO(t)exp(Pjxj + 02X2 + P3X3).
The distribution of survival time is assumed to be an
exponential one (thisisnot anessentialrestriction), and
right-censoring is not assumed. The number of strata
is 2 =8, and for each strata 4, 8, and 16 patients are
assumed. (Total number ofpatients is 32, 64, and 128.)
The order of entry of patients is randomly permuted,
and each patient is allocated deterministically into one
of two arms with the minimum total of marginal fre-
quency. The figures in the table are actual significance
levels for null hypothesis. For Ps, two sets of values
(setting 1: 0.77, setting 2: 1.54) are assumed.
Conservativeness is clear from Table 1, and it is cer-
tain there is a power loss ifthe covariates are ignored.
A little liberalism seen in the stratified analysis with a
small number (4) ofpatients in each stratum may be a
problembecause ofdependence betweenthe numerator
and the denominator of the Mantel-Haenszel type sta-
tistics, which is pointed out by Brown (9).
Permutation Tests and Development
of a Computer Program
Adesign-based analysisforclinicaltrialdataallocated
by the dynamic balancing is theoretically possible even
for the minimization method. In a deterministic case,
simulation can be carried out by pernuting the order
oftheentryofpatients (10); inaprobabilistic casewhere
Table 1. Conservativeness due to ignoring covariates in
minimization. Type I error (actual significance level):
number of iteration is 5000.'
Unstratified long-rank Stratified log-rank
N 5% 10% 5% 10%
Setting 1
32 3.5% 7.6 6.4b Me
64 2.8 6.4 5.6 10.4
128 2.9 6.8 5.8 10.7
Setting 2
32 1.0 2.8 5.9 11.3
64 0.7 2.2 5.8 10.6
128 0.5 2.3 5.5 10.6
'SE of simulation 1% = 0.20; 5% = 0.31; 10% = 0.42; N, total
sample size.
bMay be a problem ofMantel-Haenszel procedure in smallsanples
pointed out by Brown (9).
the allocation is done using a biased coin, random num-
bers can be generated by fixing the order ofthe entry
(11). Kalish and Begg (2), however, state that "these
methods require specialized computer programming
and we are unaware oftheir use in practice."
We have developed a computer program for pernu-
tation tests to test the difference of survival times in
two independent groups. This program can cope with
the following two designs: deterministic minimization
with Zelen's option (12) thatprohibits severe imbalance
within each institution, and stratified permuted block
design within each institution where the block size is
less than or equal to 8. (Permutation is carried out by
fixing the number ofpatients allocated to each group in
each block.) At present, the limitation of the problem
is as follows: number ofinstitution is less than or equal
to 50, number ofthe total oflevels ofcovariates (strat-
ifying variables) is less than orequal to 50, and number
ofpatients is less than or equal to 500.
Statisticsforwhichpermutationdistributionsarecal-
culated are the log-rank statistics and the Peto-Pren-
tice-type generalized Wilcoxon statistics. For the min-
imization method, both stratified and unstratified
statistics are calculated.
This program is written in FORTRAN 77, and the
number of lines is about 1600 without comments. This
program only outputs the simulation result into an ex-
ternalfile; theanalysisincludingcalculation ofp-values,
tabulation, and graphic presentation is carried out by
SAS. Examples ofthe execution time (by Hitachi M680
with about 20 MIPS) are included in Table 2. We are
planning to carry out 5000 to 10000 iterations in prac-
tice, and the execution time is reasonable as well as
realistic if we can use a high-speed computer. (Fortu-
nately we can.)
Currently we have no real example of permutation
tests for the minimization method because the trial us-
ing the minimization is now under way. Figure 1 is a
pernutation distribution of the log-rank statistics for
real clinical trial data. In this trial, the treatment al-
locationwas doneusingapermuted blockdesignwithin
each institute (block size: 4) and the total number of
patients was 96. There were 45 blocks in all, only four
ofwhichwere complete, andin22, onlyoneofthetreat-
ments was allocated. The Mantel-Haenszel variance of
the unstratified log-rank statistics is 13.5 and the per-
mutation variance is 9.5; the p-value of the former is
0.531 by normal approximation, and the p-value calcu-
lated from the permutation distribution is 0.486. The
bias of the center of the distribution from 0 seen in
Figure 1 is due to the imbalance of the treatment al-
Table 2. Examples ofthe execution time.'
Examples Patients Iterations Minutes
Pernuted block 100 1,000 0.1
100,000 12.0
Minimization 200 10,000 2.5
60 1,000 4.0
'By Hitachi M680 with approximately 20 MIPS.
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FIGURE 1. Permutation distribution oflog-rank statistics (a real example: 96 patients, permuted block design).
.626
location within blocks. In this example, the treatment
effect is not significant inboth analyses; but in a critical
setting, a significant result may be derived by the per-
mutation test, not by a simple analysis.
Discussion and a Suggestion
The validity ofour permutation tests is based on the
indifference ofcensoring patterns (distributions) in two
treatment groups, and the check of this assumption is
necessaryinpractice. Foradeterministic minimization,
there should not be a time trend in patients' response
for the permutation test to be valid. When this as-
sumption is doubtful, the probabilistic scheme using a
biased coin should be adopted for avoiding possible
biases.
We regard a permutation test as a kind ofinsurance;
we expect that the result ofapermutation test does not
differ essentially from that ofa stratified analysis, and
the former reinforces the latter as well as the result of
model-based analyses. But we should note that there is
no theoretical justification for stratified analysis (es-
pecially, for its power), and relying only on the model-
based analysis is sometimes hazardous inthe credibility
ofthe derived conclusion.
Data Management in Cancer Clinical
Trials
Since 1985 an international group ofresearchers has
beentrying to establish aninternational minimalguide-
line (consensus) for clinical research in bladder cancer;
the first international meeting was held in Antwerp in
1985 and the second, in Japan in 1987. The papers re-
sulting from the first conference are compiled by Denis
et al. (13).
One specific feature ofthis conference is that contri-
butions from statisticians and data managers are ex-
pected and welcomed, and four working groups of 21
researchers are devotedto discussingthe biostatistical/
managemental problems in the second conference. The
titles of the working groups are as follows: Statistical
Analysis and Sample Size Determination, Determina-
tion of Prognostic Factors, Policy on Reporting and
Publishing, and Data Management.
The fourth group consisted of three U.S./European
datamanagers, three statisticians includingthe author,
and several clinicians includingthreeJapanese. The re-
sults of a long and earnest group discussion are sum-
marized by De Pauw et al. (14). This working group
presented the first opportunity between Japanese cli-
nicians and U.S./European researchers to discuss ways
ofconducting cancer clinical trials and the organization
for quality control. Japanese clinicians confessed that
learning about a well-organized system of U.S./Euro-
peanclinicaltrialsconductedinstatistical(coordinating)
centers was a kind of cultural shock because such in-
formation is difficult to get from research papers and
absolutely different from their familiar Japanese sys-
tem.
The working group found that there is diverse ter-
minology for the samejob (Table 3), there is no statis-
tical center in Japan for cancer clinical trials, and or-
ganization in hospitals for collecting data and quality
control ranges from a very elementary level to ahighly
sophisticated one from country to country. The group
concludedthatreachingaconsensusontheorganization
of data collection and quality control is too ambitious
and consensus should be on what should be done rather
than by whom it should be done. The paper proposed a
minimal guideline on the following items: protocol de-
sign; form design; collection of forms; computerization
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Table 3. Job titles in cancer clinical trials.
Europe U.S. Japan
Study coordinator Study coordinator Chiefinvestigator
Study chairman
Protocol chairman
Data manager Data coordinator
(statistical Data administrator
center) Data manager
Local data manager Clinic coordinator
(at the hospital) Institutional data
manager
Research assistant
Research study nurse
Statistician Statistician Controller
ofinformation; feedback from the statistical center; and
organization within the hospitals including the review
ofpatient's history, cystoscopic procedure, protocol en-
try, protocoltreatment, protocolfollow-up, quality con-
trol, and forn completion.
In the formal organization in Japanese clinical trials
(Table 3), the titles of data manager and data coordi-
nator are missing, and the same role is usually played
by persons in pharmaceutical companies who visit cli-
nicians' offices, collect data forms, and check the com-
pletenessofthem. Itispossibletoclassifycancerclinical
trials from many viewpoints, and an important classi-
fication criterion is who supports the trial in data man-
agement and givesfinancial support. InJapanthere are
manyscientifically valuable cancerclinicaltrialsthatare
initiated by researchers themselves. When conducting
such a trial, researchers are lucky ifthey can get sup-
port from a company because many troublesome activ-
ities for data management and quality control are car-
riedoutbythecompany. (Usuallythecompanysupports
chemotherapy trials that use the drugthey are selling.)
The problem comes in a trial that is conducted without
such support.
ThreeJapanese clinicians, Dr. K. Obata(NagoyaSec-
ond Red-Cross Hospital), Dr. T. Uyama (Shikoku Can-
cerCenterHospital), and Dr. Y. Matsumura (Okayama
University Hospital), who attended the working group
on data management and sumnarized the difference
between the U.S./European system that was adopted
in statistical centers and theJapanese system in cancer
clinical trials that were initiated and conducted by re-
searchers (4). Table 4 gives a summary and description
of the present problems in data management and the
quality ofJapanese cancer clinical trials (statements in
the parenthesis are comments by the author).
We think the direct import ofU.S./European system
isneitherpossiblenorbeneficialbecausetherearegreat
differences in the Japanese cultural background and
those in U.S./European countries. Looldng for the re-
liable and effective research system for cancer clinical
trials, especially for data management and quality con-
trol, is a big assignment for Japanese biostatisticians
involved in clinical trials, and such biostatistical input
Table 4. A summary of present problems in data management
and the quality ofJapanese cancer clinical trials, comparing
Japanese methods with U.S./European methods.
U.S./European methods Japanese methods
Design ofdata forms
Forms are designed from a Data forms are a part ofthe
protocol by the study protocol and are designed
coordinator with the help of independently. (Sometimes
the experienced data manager. inconsistency exists between the
forms and the documented
protocol.)
Data completion
Usually forms are completed Forms are completed by doctors
by medical secretaries. themselves. (Urgent prompts
are necessary to have the
doctors fill the forms, but no
problems exists due to
inexperienced secretaries filling
out the forms.)
Collection ofdata forms
Immediately after completion. Collection is done often after a
There is an urgent prompt for committee ofleading clinicians
forms from the data manager requests the data forms. (There
in the center. may be a serious delay.)
Data check
The data manager in the The doctor is asked about
center is responsible for data questionable data when they are
checks and he/she asks the summarized or analyzed.
local data manager about
questionable data so that the
problems are settled at an
early stage.
Pathology
Prepared pathological All diagnoses are done by local
specimens are collected and pathologists, based on the
the central pathologists gives published guidelines, but there
the grading and staging. is no external reviewing system.
Quality control in general
Quality control is a The essential attitude in quality
collaborative work among assurance is to trust the doctor.
clinicians, data managers, and Quality control procedures are
statisticians. Procedures are implicit, ifany.
documented explicitly.
will contribute much to the quality ofJapanese clinical
research.
REFERENCES
1. Simon, R., and Wittes, R. E. Methodologicguidelinesforreports
ofclinical trials. Cancer Treat. Rep. 69: 1-3 (1985).
2. Kalish, L. A., and Begg, C. B. Treatment allocation methods in
clinical trials: a review. Stat. in Med. 4: 129-144 (1985).
3. Pocock, S. ClinicalTrials, JohnWileyand Sons, NewYork, 1983.
4. Ohashi, Y. Randomization in cancer clinical trials (inJapanese).
Proceedings ofthe Society for Survival Time Studies on Cancer
Patients 8: 99-111 (1988).
5. Sakamoto, J., Ichihashi, H., Koike, A., Nakazato, H., Ohashi,
Y., Tamura, H., Fujii, T., and Ogawa, N. The miiniization
method in a median-size clinical trial [in Japanese]. Jpn. Cancer
Chemother. 15: 1935-1942 (1988).
6. Green, S. B., and Byar, D. The effect ofstratified randomizationRANDOMIZATION IN CANCER CLINICAL TRIALS 17
of size and power of statistical tests in clinical trials. J. Chron.
Dis. 31: 445-454 (1978).
7. Forsythe, A. B., and Stitt, F. W. Randomization orminimization
in the treatment assignment of patient trials. Technical Report
No. 28, Health Science Computing Center, University of Cali-
fornia at Los Angeles, Los Angeles, CA, 1977.
8. Kalish, L. A., and Begg, C. B. Theimpact oftreatment allocation
procedures on nominal significance levels and bias. Control. Clin.
Trials 8: 121-135 (1987).
9. Brown, M. On the choice ofvariances for the log-rank test. Bio-
metrika 71: 65-74 (1984).
10. Simon, R. Restricted randomization designs inclinical trials. Bio-
metrics 35: 503-512 (1979).
11. Brown, B. W. Statistical controversies in the design of clinical
trials-some personal views. Control. Clin. Trials 1: 13-27 (1980).
12. Zelen, M. The randomization and stratification ofpatients to clin-
ical trials. J. Chron. Dis. 27: 365-375 (1974).
13. Denis, L., Niiima, T., Prout, G., and Schroder, F. H., Eds.
Developments in Bladder Cancer. Alan R. Liss Inc., New York,
1986.
14. De Pauw, M., Griffin, P., Ohashi, Y., Geboers, A., Hilgar, A.,
Obata, K., Uyama, T., Matsumura, Y., Rozek, S., Van Reijs-
woud, I., Birch, R., Barton, B., Hammond, B., and Staquet, M.
Minimalguidelinesfortheorganization ofdatacollectionandqual-
ity control in multicenter clinical trials. In: Development in Blad-
der Cancer, Vol. 2. Alan R. Liss Inc., New York, in press.